Download PDF
Indian Journal of Neurotrauma 2008; 05(01): 41-44
DOI: 10.1016/S0973-0508(08)80028-7
Drug Review
Thieme Medical and Scientific Publishers Private Ltd.

Propofol in Neurotrauma

TVSP Murthy
Subject Editor:
Further Information

Publication History

Publication Date:
05 April 2017 (online)

  PDF Download  Permissions and Reprints

Abstract

Propofol (2,6-diisopropylphenol) is one of the most popular agents used for induction of anesthesia and long-term sedation, owing to its favorable pharmacokinetic profile, which ensures a rapid recovery even after prolonged administration. Propofol is used widely as a sedative agent in neurosurgical critical care because it is generally assumed that it has properties that are advantageous to the injured brain. Propofol is believed to maintain, or even improve, cerebral autoregulation, indeed even high doses of this drug do not obtund autoregulation or carbon dioxide reactivity. A neuroprotective effect, beyond that related to the decrease in cerebral metabolic rate for oxygen, has been shown to play an important role in the so-called multimodal neuroprotection, a global strategy for the treatment of acute injury of the brain that includes preservation of cerebral perfusion, temperature control, prevention of infections, and tight glycaemic control.

Keywords

propofol - neuroprotection - traumatic brain injury
 

  • References

  • 1 Kawaguchi M, Furuya H, Patel PM. Neuroprotective effects of anesthetic agents. J Anesth 19 2005; 150-156
    CrossrefPubMedGoogle Scholar
  • 2 Koerner IP, Brambrink AM. Brain protection by anesthetic agents. Curr Opin Anaesthesiol 19 2006; 481-486
    CrossrefPubMedGoogle Scholar
  • 3 James R, Glen JB. Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents. J Med Chem 23 1980; 1350-1357
    CrossrefPubMedGoogle Scholar
  • 4 Kay B, Rolly GICI. 35868, a new intravenous induction agent. Acta Anaesthesiol Belg 28 1977; 303-306
    PubMedGoogle Scholar
  • 5 Borgeat A, Wilder-Smith O, Forni M, Suter PM. Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer. Can J Anaesth 41 1994; 1117-1119
    CrossrefPubMedGoogle Scholar
  • 6 Orser BA, Wang LY, Pennefather PS, MacDonald JF. Propofol modulates activation and desensitization of GABAA receptors in cultured murine hippocampal neurons. J Neurosci 14 1994; 7747-7760
    PubMedGoogle Scholar
  • 7 Ratnakumari L, Hemmings Jr HC. Effects of propofol on sodium channel-dependent sodium influx and glutamate release in rat cerebrocortical synaptosomes. Anesthesiology 86 1997; 428-439
    CrossrefPubMedGoogle Scholar
  • 8 Mortero RF, Clark LD, Tolan MM, Metz RJ, Tsueda K, Sheppard RA. The effects of small-dose ketamine on propofol sedation: Respiration, postoperative mood, perception, cognition, and pain. Anesth Analg 200; 92:1465-9.
    PubMed
  • 9 Patel P. No magic bullets: the ephemeral nature of anestheticmediated neuroprotection. Anesthesiology 100 2004; 1049-1051
    CrossrefPubMedGoogle Scholar
  • 10 Kanto J, Gepts E. Pharmacokinetic implications for the clinical use of propofol. Clin Pharmacokinet 17 1989; 308-326
    CrossrefPubMedGoogle Scholar
  • 11 Bryson HM, Fulton BR, Faulds D. Propofol. An update of its use in anaesthesia and conscious sedation. Drugs 50 1995; 513-559
    CrossrefPubMedGoogle Scholar
  • 12 Wysowski DK, Pollock ML. Reports of death with use of propofol (Diprivan) for nonprocedural (long-term) sedation and literature review. Anesthesiology 105 2006; 1047-1051
    CrossrefPubMedGoogle Scholar
  • 13 Ishii H, Arai T, Segawa H, Morikawa S, Inubushi T, Fukuda K. Effects of propofol on lactate accumulation and oedema formation in focal cerebral ischaemia in hyperglycaemic rats. Br J Anaesth 88 2002; 412-417
    CrossrefPubMedGoogle Scholar
  • 14 Adembri C, Venturi L, Tani A. et al Neuroprotective effects of propofol in models of cerebral ischemia: Inhibition of mitochondrial swelling as a possible mechanism. Anesthesiology 104 2006; 80-89
    CrossrefPubMedGoogle Scholar
  • 15 Todd MM, Warner DS. A comfortable hypothesis reevaluated. Cerebral metabolic depression and brain protection during ischemia. Anesthesiology 76 1992; 161-164
    CrossrefPubMedGoogle Scholar
  • 16 Nicol B, Rowbotham DJ, Lambert DG. Glutamate uptake is not a major target site for anaesthetic agents. Br J Anaesth 75 1995; 61-65
    CrossrefPubMedGoogle Scholar
  • 17 Sitar SM, Hanifi-Moghaddam P, Gelb A, Cechetto DF, Siushansian R, Wilson JX. Propofol prevents peroxide-induced inhibition of glutamate transport in cultured astrocytes. Anesthesiology 90 1999; 1446-1453
    CrossrefPubMedGoogle Scholar
  • 18 Velly LJ, Guillet BA, Masmejean FM. et al Neuroprotective effects of propofol in a model of ischemic cortical cell cultures: Role of glutamate and its transporters. Anesthesiology 99 2003; 368-375
    CrossrefPubMedGoogle Scholar
  • 19 Williams DB, Akabas MH. Structural evidence that propofol stabilizes different GABAA receptor states at potentiating and activating concentrations. J Neurosci 22 2002; 7417-7424
    PubMedGoogle Scholar
  • 20 Mattson MP, Kroemer G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol Med 09 2003; 196-205
    CrossrefPubMedGoogle Scholar
  • 21 Van Der Stelt M, Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromol Med 07 2005; 37-50
    CrossrefPubMedGoogle Scholar
  • 22 Fox J, Gelb AW, Enns J, Murkin JM, Farrar JK, Manninen PH. The responsiveness of cerebral blood flow to changes in arterial carbon dioxide is maintained during propofol-nitrous oxide anesthesia in humans. Anesthesiology 77 1992; 453-456
    CrossrefPubMedGoogle Scholar
  • 23 Walder B, Tramer MR, Seeck M. Seizure-like phenomena and propofol: A systematic review. Neurology 58 2002; 1327-1332
    CrossrefPubMedGoogle Scholar
  • 24 Gupta A, Stierer T, Zuckerman R, Sakima N, Parker SD, Fleisher LA. Comparison of recovery profile after ambulatory anesthesia with propofol, isoflurane, sevoflurane and desflurane: A systematic review. Anesth Analg 98 2004; 632-641
    PubMedGoogle Scholar
  • 25 Preckel B, Weber NC, Sanders RD, Maze M, Schlack W. Molecular mechanisms transducing the anesthetic, analgesic, and organ-protective actions of xenon. Anesthesiology 105 2006; 187-197
    CrossrefPubMedGoogle Scholar